GTx, Inc. - Product Pipeline Review - 2016

  • ID: 3759035
  • Company Profile
  • 47 pages
  • Global Markets Direct
1 of 4
GTx, Inc. - Product Pipeline Review - 2016

Summary

‘GTx, Inc. - Product Pipeline Review - 2016’, provides an overview of the GTx, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by GTx, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of GTx, Inc.
- The report provides overview of GTx, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses GTx, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features GTx, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate GTx, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for GTx, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding GTx, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

GTx, Inc. Snapshot

GTx, Inc. Overview

Key Information

Key Facts

GTx, Inc. - Research and Development Overview

Key Therapeutic Areas

GTx, Inc. - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

GTx, Inc. - Pipeline Products Glance

GTx, Inc. - Clinical Stage Pipeline Products

Phase II Products/Combination Treatment Modalities

GTx, Inc. - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

GTx, Inc. - Drug Profiles

enobosarm

Product Description

Mechanism of Action

R&D Progress

GTx-758

Product Description

Mechanism of Action

R&D Progress

Beta-LGND2

Product Description

Mechanism of Action

R&D Progress

GTx-026

Product Description

Mechanism of Action

R&D Progress

Gtx-027

Product Description

Mechanism of Action

R&D Progress

Gtx-186

Product Description

Mechanism of Action

R&D Progress

Gtx-230

Product Description

Mechanism of Action

R&D Progress

GTx-878

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Antagonize Androgen Receptor for Metastatic Castration Resistant Prostate Cancer

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Inhibit AKR1C3 for Prostate Cancer and Castration Resistant Prostate Cancer

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Inhibit Tubulin for Cancer

Product Description

Mechanism of Action

R&D Progress

GTx, Inc. - Pipeline Analysis

GTx, Inc. - Pipeline Products by Target

GTx, Inc. - Pipeline Products by Route of Administration

GTx, Inc. - Pipeline Products by Molecule Type

GTx, Inc. - Pipeline Products by Mechanism of Action

GTx, Inc. - Recent Pipeline Updates

GTx, Inc. - Dormant Projects

GTx, Inc. - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

toremifene citrate

GTx, Inc. - Company Statement

GTx, Inc. - Locations And Subsidiaries

Head Office

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

GTx, Inc., Key Information

GTx, Inc., Key Facts

GTx, Inc. - Pipeline by Indication, 2016

GTx, Inc. - Pipeline by Stage of Development, 2016

GTx, Inc. - Monotherapy Products in Pipeline, 2016

GTx, Inc. - Phase II, 2016

GTx, Inc. - Preclinical, 2016

GTx, Inc. - Pipeline by Target, 2016

GTx, Inc. - Pipeline by Route of Administration, 2016

GTx, Inc. - Pipeline by Molecule Type, 2016

GTx, Inc. - Pipeline Products by Mechanism of Action, 2016

GTx, Inc. - Recent Pipeline Updates, 2016

GTx, Inc. - Dormant Developmental Projects,2016

GTx, Inc. - Discontinued Pipeline Products, 2016

List of Figures

GTx, Inc. - Pipeline by Top 10 Indication, 2016

GTx, Inc. - Pipeline by Stage of Development, 2016

GTx, Inc. - Monotherapy Products in Pipeline, 2016

GTx, Inc. - Pipeline by Target, 2016

GTx, Inc. - Pipeline by Route of Administration, 2016

GTx, Inc. - Pipeline by Molecule Type, 2016

GTx, Inc. - Pipeline Products by Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll